ArticleAnnals of translational medicine2020
Ginsenoside Rg1 prevents early diabetic retinopathy
Article in Annals of translational medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Antioxidant and anti-inflammatory properties of ginsenoside Rg1 for hyperglycemia in type 2 diabetes mellitus: systematic reviews and meta-analyses of animal studies.Frontiers in pharmacology · 2023Pooled it
- Review
- Review
- Beneficial Effects of Natural Bioactive Compounds on Eye Health: A Narrative Review.International journal of molecular sciences · 2026Review
- Ginsenoside Rg1 ameliorates the senescence and neurite injury of retinal ganglion cells in DR via targeting VDR and promoting mitochondrial biogenesis.Journal of ginseng research · 2026Article
- Ginsenoside Rg1 alleviates HG-induced autophagy of retinal microvascular endothelial cells by activating ACE2/Ang1-7/Mas in vitro.Scientific reports · 2025Article
- Elucidating programmed cell death in diabetic retinal microangionopathy and neurodegeneration: unraveling molecular mechanisms and therapeutic actions of natural products.Inflammopharmacology · 2025Review
- RBM15 promotes m6A methylation and stability of KLF6 mRNA to accelerate pyroptosis of retinal ganglion cells in early-stage diabetic retinopathy.Journal of molecular histology · 2025Article
- The integration of spear and shield: a panoramic analysis of the blood circulation-promoting and hemostatic effects of Panax notoginseng.Chinese medicine · 2025Review
- Clinical observations and mechanistic insights of traditional Chinese medicine in the management of diabetic retinopathy.Pharmaceutical biology · 2024Review
- Nutraceuticals for Diabetic Retinopathy: Recent Advances and Novel Delivery Systems.Nutrients · 2024Review
- Diabetic Retinopathy: New Treatment Approaches Targeting Redox and Immune Mechanisms.Antioxidants (Basel, Switzerland) · 2024Review
- Compound Danshen dripping pills prevent early diabetic retinopathy: roles of vascular protection and neuroprotection.Frontiers in pharmacology · 2024Article
- GRg1 inhibits the TLR4/NF-kB signaling pathway by upregulating miR-216a-5p to reduce growth factors and inflammatory cytokines in DR.Molecular biology reports · 2023Article
- Ginsenoside Rg1 Inhibits High Glucose-Induced Proliferation, Migration, and Angiogenesis in Retinal Endothelial Cells by Regulating the lncRNA SNHG7/miR-2116-5p/SIRT3 Axis.Journal of oncology · 2022Article
- Retinal Neurodegeneration in Diabetes: an Emerging Concept in Diabetic Retinopathy.Current diabetes reports · 2021Review
- Correlation of Retinal Structure and Visual Function Assessments in Mouse Diabetes Models.Investigative ophthalmology & visual science · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiabetic retinopathy (DR), a diabetic vascular complication, is prone to developing into blindness. Ginsenoside Rg1 (GRg1), a major saponin in ginseng, exerts high anti-apoptotic activity.
methodsThis study aimed to explore the protective effects of GRg1 against diabetes-induced retinal damage. Measurements of blood glucose, blood lipids and vascular permeability were performed, as well as assessments of pathological changes, and the retinal thickness of each layer. Retinal cell apoptosis related protein expression levels were measured by immunofluorescence and western blot assays.
resultsOur data demonstrated that GRg1 effectively reduced blood glucose and triglyceride levels and maintained normal retinal permeability and physiological structure. GRg1 maintained the thickness of the ganglion cell layer (GCL) and the inner nuclear layer (INL) by reducing cell apoptosis.
conclusionsThese data strongly indicate that GRg1 prevents diabetic retinal changes by decreasing GCL and INL cell apoptosis. GRg1 may be a promising drug for early DR treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.